These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9888307)

  • 1. Development and in vitro evaluation of a drug delivery system based on chitosan-EDTA BBI conjugate.
    Bernkop-Schnürch A; Krauland A; Valenta C
    J Drug Target; 1998; 6(3):207-14. PubMed ID: 9888307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats.
    Krauland AH; Guggi D; Bernkop-Schnürch A
    J Control Release; 2004 Mar; 95(3):547-55. PubMed ID: 15023465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal peptide and protein delivery: novel bioadhesive drug-carrier matrix shielding from enzymatic attack.
    Bernkop-Schnürch A; Pasta M
    J Pharm Sci; 1998 Apr; 87(4):430-4. PubMed ID: 9548894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, development and in vitro evaluation of drug delivery systems with protective effect against degradation by pepsin.
    Bernkop-Schnürch A; Kirchmayer R; Kratzel M
    J Drug Target; 1999; 7(1):55-63. PubMed ID: 10614815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates.
    Bernkop-Schnürch A; Krajicek ME
    J Control Release; 1998 Jan; 50(1-3):215-23. PubMed ID: 9685888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro.
    Marschütz MK; Bernkop-Schnürch A
    Biomaterials; 2000 Jul; 21(14):1499-507. PubMed ID: 10872779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro study of different chitosan-complexing agent conjugates.
    Bernkop-Schnürch A; Freudl J
    Pharmazie; 1999 May; 54(5):369-71. PubMed ID: 10368830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases.
    Guggi D; Bernkop-Schnürch A
    Int J Pharm; 2003 Feb; 252(1-2):187-96. PubMed ID: 12550794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
    Yavelow J; Caggana M; Beck KA
    Cancer Res; 1987 Mar; 47(6):1598-601. PubMed ID: 3545448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of thiolated polymers as carrier matrix in oral peptide delivery--proof of concept.
    Bernkop-Schnürch A; Pinter Y; Guggi D; Kahlbacher H; Schöffmann G; Schuh M; Schmerold I; Del Curto MD; D'Antonio M; Esposito P; Huck C
    J Control Release; 2005 Aug; 106(1-2):26-33. PubMed ID: 15939501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB; Kennedy AR; Wan XS; Atiba J; McLaren CE; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):43-7. PubMed ID: 10667462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiolated chitosan microparticles: a vehicle for nasal peptide drug delivery.
    Krauland AH; Guggi D; Bernkop-Schnürch A
    Int J Pharm; 2006 Jan; 307(2):270-7. PubMed ID: 16300914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems.
    Bernkop-Schnürch A
    Int J Pharm; 2000 Jan; 194(1):1-13. PubMed ID: 10601680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor.
    St Clair WH; Billings PC; Carew JA; Keller-McGandy C; Newberne P; Kennedy AR
    Cancer Res; 1990 Feb; 50(3):580-6. PubMed ID: 2297699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir.
    Palmberger TF; Hombach J; Bernkop-Schnürch A
    Int J Pharm; 2008 Feb; 348(1-2):54-60. PubMed ID: 17716840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinase inhibition using small Bowman-Birk-type structures.
    Fernandez JH; Mello MO; Galgaro L; Tanaka AS; Silva-Filho MC; Neshich G
    Genet Mol Res; 2007 Oct; 6(4):846-58. PubMed ID: 18058707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
    Ware JH; Wan XS; Rubin H; Schechter NM; Kennedy AR
    Arch Biochem Biophys; 1997 Aug; 344(1):133-8. PubMed ID: 9244390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix.
    Guggi D; Kast CE; Bernkop-Schnürch A
    Pharm Res; 2003 Dec; 20(12):1989-94. PubMed ID: 14725364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Structure and biological properties of a conjugate of Bowman-Birk type soy proteinase inhibitor with a block copolymer of ethylene oxide and propylene oxide].
    Gladysheva IP; Polekhina OV; Shen WC; Shevchenko AA; Kazanskaia NF; Larionova NI
    Biokhimiia; 1995 Apr; 60(4):523-32. PubMed ID: 7779975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity.
    Malkowicz SB; Liu SP; Broderick GA; Wein AJ; Kennedy AR; Levin RM
    Neurourol Urodyn; 2003; 22(1):54-7. PubMed ID: 12478602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.